Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Soligenix, Inc. - Common Stock
(NQ:
SNGX
)
1.570
-0.060 (-3.68%)
Streaming Delayed Price
Updated: 11:17 AM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Soligenix, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies
Today 9:23 EST
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
Today 8:30 EST
From
Soligenix, Inc.
Via
GlobeNewswire
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
December 04, 2025
Via
Investor Brand Network
Topics
Government
Soligenix Logs Best Session In Nearly 2 Months After Safety Win In T-Cell Lymphoma Trial — Traders Eye Multiday Rally
↗
October 08, 2025
Via
Stocktwits
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
December 04, 2025
From
BioMedWire
Via
GlobeNewswire
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial Highlighting HyBryte(TM) and Rare Disease Policy
December 03, 2025
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
December 03, 2025
From
Soligenix, Inc.
Via
GlobeNewswire
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
December 02, 2025
Via
Investor Brand Network
Topics
Government
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
December 02, 2025
From
BioMedWire
Via
GlobeNewswire
Soligenix Inc. (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate
December 01, 2025
Via
Investor Brand Network
Study Uncovers Surprising Connection Between Choline, Obesity and Brain Inflammation
December 01, 2025
Via
Investor Brand Network
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Heat-Stable Vaccine Platform with New Peer-Reviewed Data
November 28, 2025
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Elevates Advisory Network as Rare Disease Strategy Advances
November 25, 2025
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Strengthens CTCL Program as DMC Flags No Safety Issues
November 24, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte
November 19, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte
November 19, 2025
Via
Investor Brand Network
Parent Explains Why it is Wrong to Say Vaccines Cause Autism
November 18, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Key Clinical Progress and Reports Q3 2025 Financial Results
November 07, 2025
Via
Investor Brand Network
Surface Sugars on Immune Cells Linked to the Progression of Psoriasis
November 07, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Eyes Dermatology Market with SGX302’s Encouraging Early Results
November 06, 2025
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Strengthens Financial Foundation to Advance Multiple Value Drivers
November 04, 2025
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Strengthens Advisory Leadership in Cutaneous T-Cell Lymphoma
November 03, 2025
Via
Investor Brand Network
Topics
Retirement
$37.5M Grant Announced to Boost Management of Infectious Diseases in the US
October 30, 2025
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Research Highlights Breakthrough in High-Temperature Vaccine Stability
October 28, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advances HyBryte(TM) as Potential First-Line CTCL Treatment with Promising FLASH Results
October 22, 2025
Via
Investor Brand Network
Researchers Develop Nanoparticles That Could Combat Scarring, Inflammation in ARLD
October 21, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Updates U.S. Medical Advisory Board to Advance Phase 3 Development of HyBryte for CTCL
October 14, 2025
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026
October 13, 2025
Via
Investor Brand Network
How You Can Support Your Loved One Undergoing Cancer Treatment
October 10, 2025
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL
October 09, 2025
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today